IQVIA Holdings Inc. (IQV) Stock Analysis
By stockpickr AI | March 3, 2026 | 10 min read
Investment Summary
IQVIA is a key player in the healthcare technology and clinical research sector, and based on the DCF valuation, it appears to be slightly overvalued relative to current intrinsic value estimates.
Investment Recommendation
Hold
Fair Value: $185.50
Current Price: $197.12
Upside/Downside: -5.89%
The DCF analysis suggests an implied fair value slightly below the current market price of $197.12. The valuation reflects solid growth prospects but is tempered by premium trading multiples reflective of its market position, leading to a neutral assessment.
Key Metrics
- Market Cap: $43.96B
- P/E Ratio: 29.46x
- Forward P/E: 23.85x
- Revenue Growth (YoY): 5.3%
- Net Margin: 12.4%
- ROE: 30.2%
- Debt/Equity: 1.25
- Dividend Yield: 0.38%
Strengths
- Market leadership in outsourced clinical R&D services with a vast proprietary data asset.
- Strong recurring revenue streams anchored by long-term customer contracts.
- Healthy recent revenue growth of 5.3% YoY (Q1 2024 results).
- High Return on Equity (ROE) of 30.2% indicating efficient use of shareholder capital.
Risk Factors
- High leverage (Debt/Equity of 1.25) increases financial risk, especially in a rising interest rate environment.
- Potential for slower growth if pharmaceutical industry customers internalize more R&D functions.
- Integration and execution risks associated with past major mergers and ongoing platform development.